XML 39 R29.htm IDEA: XBRL DOCUMENT
v3.25.2

Schedule of Significant Expense Categories and Consolidated Net Loss (Details) - USD ($) | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2025 | Jun. 30, 2024 | Jun. 30, 2025 | Jun. 30, 2024
Segment Reporting Information [Line Items] |  |  |  |
Research and development expenses | $ 1,226,954 | $ 2,819,645 | $ 3,392,046 | $ 6,113,506
General and administrative expenses | 1,540,910 | 2,193,706 | 3,521,117 | 3,911,291
Total operating expenses | 2,767,864 | 5,013,351 | 6,913,163 | 10,024,797
Loss from operations | $ (2,767,864) | $ (5,013,351) | (6,913,163) | (10,024,797)
Operating Segments [Member] |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Change Increase (Decrease), Research and development expenses |  |  | (2,722,000) |
Research and development expenses |  |  | $ 3,392,000 | 6,114,000
Change Increase (Decrease), Research and development expenses, percentage |  |  | (44.50%) |
General and administrative expenses |  |  | $ 3,521,000 | 3,911,000
Change Increase (Decrease), General and administrative expenses |  |  | $ (390,000) |
Change Increase (Decrease), General and administrative expenses, percentage |  |  | (10.00%) |
Total operating expenses |  |  | $ 6,913,000 | 10,025,000
Change Increase (Decrease), Operating expenses |  |  | $ (3,112,000) |
Change Increase (Decrease), Operating expenses, percentage |  |  | (31.00%) |
Loss from operations |  |  | $ (6,913,000) | (10,025,000)
Change Increase (Decrease), Loss from operations |  |  | $ (3,112,000) |
Change Increase (Decrease), Loss from operations, percentage |  |  | (31.00%) |
Operating Segments [Member] | Clinical Research [Member] |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Subtotal |  |  | $ 1,366,000 | 2,710,000
Change Increase (Decrease), Research and development expenses |  |  | $ (1,344,000) |
Change Increase (Decrease), Subtotal, percentage |  |  | (49.60%) |
Operating Segments [Member] | Clinical Research [Member] | Ovation [Member] |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Subtotal |  |  | $ 382,000 | 721,000
Change Increase (Decrease), Research and development expenses |  |  | $ (339,000) |
Change Increase (Decrease), Subtotal, percentage |  |  | (47.00%) |
Operating Segments [Member] | Clinical Research [Member] | Placcine Vaccine [Member] |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Subtotal |  |  | $ 33,000 | 889,000
Change Increase (Decrease), Research and development expenses |  |  | $ (856,000) |
Change Increase (Decrease), Subtotal, percentage |  |  | (96.30%) |
Operating Segments [Member] | Clinical Research [Member] | Other Clinical And Regulatory [Member] |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Subtotal |  |  | $ 951,000 | 1,100,000
Change Increase (Decrease), Research and development expenses |  |  | $ (149,000) |
Change Increase (Decrease), Subtotal, percentage |  |  | (13.50%) |
Operating Segments [Member] | Non-Clinical R&D and CMC [Member] |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Subtotal |  |  | $ 2,026,000 | 3,404,000
Change Increase (Decrease), Research and development expenses |  |  | $ (1,378,000) |
Change Increase (Decrease), Subtotal, percentage |  |  | (40.50%) |
Operating Segments [Member] | Non-Clinical R&D and CMC [Member] | Ovation [Member] |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Subtotal |  |  | $ 1,485,000 | 652,000
Change Increase (Decrease), Research and development expenses |  |  | $ 833,000 |
Change Increase (Decrease), Subtotal, percentage |  |  | 127.80% |
Operating Segments [Member] | Non-Clinical R&D and CMC [Member] | Placcine Vaccine [Member] |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Subtotal |  |  |  | 1,956,000
Change Increase (Decrease), Research and development expenses |  |  | $ (1,956,000) |
Change Increase (Decrease), Subtotal, percentage |  |  |  |
Operating Segments [Member] | Non-Clinical R&D and CMC [Member] | Manufacturing (CMC) [Member] |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Subtotal |  |  | $ 541,000 | $ 796,000
Change Increase (Decrease), Research and development expenses |  |  | $ (255,000) |
Change Increase (Decrease), Subtotal, percentage |  |  | (32.00%) |

X
- Definition Increase decrease in general and administrative expenes. + References No definition available. + Details
Name: | IMNN_IncreaseDecreaseInGeneralAndAdministrativeExpenes
Namespace Prefix: | IMNN_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Increase decrease in general and administrative expenses percentage. + References No definition available. + Details
Name: | IMNN_IncreaseDecreaseInGeneralAndAdministrativeExpensesPercentage
Namespace Prefix: | IMNN_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase decrease in loss from operations. + References No definition available. + Details
Name: | IMNN_IncreaseDecreaseInLossFromOperations
Namespace Prefix: | IMNN_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Increase decrease in loss from operations percentage. + References No definition available. + Details
Name: | IMNN_IncreaseDecreaseInLossFromOperationsPercentage
Namespace Prefix: | IMNN_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase decrease in operating cost and expenses. + References No definition available. + Details
Name: | IMNN_IncreaseDecreaseInOperatingCostAndExpenses
Namespace Prefix: | IMNN_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Increase decrease in operating costs and expenses percentage. + References No definition available. + Details
Name: | IMNN_IncreaseDecreaseInOperatingCostsAndExpensesPercentage
Namespace Prefix: | IMNN_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase decrease in operating expenses. + References No definition available. + Details
Name: | IMNN_IncreaseDecreaseInOperatingExpenses
Namespace Prefix: | IMNN_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Increase decrease in operating expenses percentage. + References No definition available. + Details
Name: | IMNN_IncreaseDecreaseInOperatingExpensesPercentage
Namespace Prefix: | IMNN_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase decrease in research and development expenses percentage. + References No definition available. + Details
Name: | IMNN_IncreaseDecreaseInResearchAndDevelopmentExpensesPercentage
Namespace Prefix: | IMNN_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details
Name: | us-gaap_GeneralAndAdministrativeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense. + References No definition available. + Details
Name: | us-gaap_OperatingCostsAndExpenses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 + Details
Name: | us-gaap_OperatingExpenses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The net result for the period of deducting operating expenses from operating revenues. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details
Name: | us-gaap_OperatingIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=IMNN_ClinicalResearchMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=IMNN_OvationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=IMNN_PlaccineVaccineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=IMNN_OtherClinicalAndRegulatoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=IMNN_NonClinicalRAndDAndCMCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=IMNN_ManufacturingCMCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |